A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines

Completed

Conditions studied: Chronic Migraine, Headaches

In brief

This study will evaluate the effectiveness and benefit of treatment with onabotulinumtoxinA in Chronic Migraine patients who have received a minimum of 7 treatment cycles.

Key facts

Study ID

NCT01749410

Run by

Allergan

People needed

33

Starts

2013-05-01

Expected to finish

2014-05-01

Last updated by the study team

2015-09-10

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 15 or more headache days over a 30 day period
• A minimum of 7 treatment cycles with onabotulinumtoxinA

You may not qualify if…

• Any treatment cycle dose of onabotulinumtoxinA greater than 200 units

Where it is running

• Study site — Encinitas, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.